127
Participants
Start Date
February 29, 2004
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
Degarelix
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
Hudson Valley Urology PC, Poughkeepsie
State College Urologic Association, State College
Virginia Urology Center, Richmond
The Urology Center, Greensboro
South Florida Medical Research, Aventura
SW Florida Urological Associates, Fort Myers
Florida Foundation for Healthcare Research, Ocala
Urology Centers of Alabama, Homewood
Northeast Indiana Research, LLC, Fort Wayne
RMD Clinical Reseach Institution LLC, Melrose Park
Regional Urology, Shreveport
Scott & White Memorial Hospital, Temple
Urology San Antonio Research, San Antonio
Urology Associate PC, Denver
Wyoming Research Foundation, Cheyenne
Nevada Urology Associates, Reno
Pacific Clinical Research, Santa Monica
Western Clinical Research, Torrance
West Coast Clinical Research, Tarzana
South Orange County Medical Research Cnter, Laguna Woods
Advanced Urology Medical Center, Anaheim
Office of Jeffrey Frankel, Seattle
Alaska Clinical Research Center, LLC, Anchorage
Lawrenceville Urology, Lawrenceville
Univeristy Urological Research Institute, Providence
University of Vermont, Dept of Surgery, South Burlington
Southern Interior Medical Research Corporation, Kelowna
Dr. Cal Abdreau Research, Surrey
Can-Med Clinical Research, Inc., Victoria
Dr. Gary Steinhoff Clinical Research, Victoria
Valley Professional Center, Kentville
The Male and Female Health and Research Centers, Barrie
Brantford Urology Research, Brantford
Burlington Professional Care, Burlington
The Female/Male Health Centres, Oakville
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY